Cingulate Provides Management Team Update
Cingulate (NASDAQ: CING) announced significant management changes as Chairman and CEO Shane J. Schaffer has been placed on administrative leave due to legal matters unrelated to the company. Jennifer Callahan, the company's CFO, has been appointed as interim CEO while maintaining her CFO duties. Additionally, board member Jay Roberts has been named Executive Chairman.
The company recently submitted a new drug application to the FDA in July for CTx-1301, their ADHD treatment candidate. The management team includes experienced executives Dr. Matt Brams (Co-Founder and CMO), Dr. Raul Silva (Co-Founder and CSO), and Nilay Patel (CLO).
Cingulate (NASDAQ: CING) ha annunciato importanti cambiamenti dirigenziali: il Presidente e CEO Shane J. Schaffer è stato posto in congedo amministrativo per questioni legali estranee all'azienda. Jennifer Callahan, CFO della società, è stata nominata CEO ad interim mantenendo contestualmente le sue funzioni di CFO. Inoltre, il membro del consiglio Jay Roberts è stato designato Executive Chairman.
La società ha recentemente presentato alla FDA, a luglio, una nuova domanda per l'approvazione del farmaco CTx-1301, il suo candidato per il trattamento dell'ADHD. Il team di gestione comprende dirigenti esperti come il Dr. Matt Brams (Co-fondatore e CMO), il Dr. Raul Silva (Co-fondatore e CSO) e Nilay Patel (CLO).
Cingulate (NASDAQ: CING) anunció cambios significativos en la dirección: el presidente y CEO Shane J. Schaffer fue puesto en licencia administrativa por asuntos legales ajenos a la compañía. Jennifer Callahan, la CFO, ha sido nombrada CEO interina y conservará sus responsabilidades como CFO. Además, el miembro del consejo Jay Roberts fue designado Presidente Ejecutivo.
La empresa presentó recientemente en julio una nueva solicitud de fármaco a la FDA para CTx-1301, su candidato para el tratamiento del TDAH. El equipo directivo incluye a ejecutivos con experiencia: el Dr. Matt Brams (cofundador y CMO), el Dr. Raul Silva (cofundador y CSO) y Nilay Patel (CLO).
Cingulate (NASDAQ: CING)는 중요한 경영진 변동을 발표했습니다. 회장 겸 CEO인 Shane J. Schaffer는 회사와 무관한 법적 문제로 행정 휴직 조치되었습니다. Jennifer Callahan CFO가 CFO 직무는 유지하면서 임시 CEO로 선임되었습니다. 또한 이사회 멤버 Jay Roberts는 총괄 회장(Executive Chairman)으로 임명되었습니다.
회사는 최근 7월에 ADHD 치료 후보물질인 CTx-1301에 대해 FDA에 신약 신청서를 제출했습니다. 경영진에는 공동창업자 겸 CMO인 Dr. Matt Brams, 공동창업자 겸 CSO인 Dr. Raul Silva, 그리고 CLO인 Nilay Patel 등 경험 많은 임원들이 포함되어 있습니다.
Cingulate (NASDAQ: CING) a annoncé des changements majeurs dans sa direction : le président et PDG Shane J. Schaffer a été placé en congé administratif pour des affaires juridiques sans lien avec l'entreprise. Jennifer Callahan, la directrice financière, a été nommée PDG par intérim tout en conservant ses fonctions de CFO. Par ailleurs, le membre du conseil Jay Roberts a été nommé Executive Chairman.
La société a récemment déposé en juillet une nouvelle demande d'autorisation auprès de la FDA pour CTx-1301, son candidat médicament pour le traitement du TDAH. L'équipe de direction comprend des cadres expérimentés tels que le Dr Matt Brams (cofondateur et CMO), le Dr Raul Silva (cofondateur et CSO) et Nilay Patel (CLO).
Cingulate (NASDAQ: CING) hat bedeutende Personaländerungen bekanntgegeben: Vorsitzender und CEO Shane J. Schaffer wurde wegen rechtlicher Angelegenheiten, die nichts mit dem Unternehmen zu tun haben, beurlaubt. Jennifer Callahan, die CFO, wurde zur Interims-CEO ernannt und bleibt zugleich CFO. Zudem wurde Vorstandsmitglied Jay Roberts zum Executive Chairman benannt.
Das Unternehmen reichte im Juli einen neuen Arzneimittelantrag bei der FDA für CTx-1301 ein, ihren Kandidaten zur Behandlung von ADHS. Zum Managementteam gehören erfahrene Führungskräfte wie Dr. Matt Brams (Mitbegründer und CMO), Dr. Raul Silva (Mitbegründer und CSO) und Nilay Patel (CLO).
- Experienced CFO Jennifer Callahan appointed as interim CEO, ensuring leadership continuity
- Recent NDA submission to FDA for ADHD drug CTx-1301
- Appointment of healthcare industry veteran Jay Roberts as Executive Chairman
- Chairman and CEO Shane Schaffer placed on administrative leave due to legal matters
- Leadership uncertainty during critical FDA review period
Jennifer Callahan, Chief Financial Officer, appointed Interim CEO
Board member, Jay Roberts appointed Executive Chairman
KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (“Cingulate”) announced that it has placed Chairman and Chief Executive Officer, Shane J. Schaffer, PharmD, on administrative leave in connection with ongoing legal matters unrelated to the company and its operations. In addition, Jennifer Callahan, Cingulate’s Chief Financial Officer, has been appointed interim CEO to ensure business continuity and operational stability. Ms. Callahan will retain her responsibilities as Chief Financial Officer. Healthcare industry veteran and current Cingulate board member Jay Roberts has been appointed Executive Chairman, bringing decades of operational expertise to directly support the management team's strategic initiatives.
"Cingulate remains committed to its mission to bring CTx-1301 to patients with attention-deficit/hyperactivity disorder with its recent new drug application filing submission to the FDA in July. The Board has full confidence in Cingulate’s leadership team to guide the Company forward, and our commitment to science, innovation, and building shareholder value is as strong as ever. We continue to move forward with focus and a steadfast dedication," said Jay Roberts, Executive Chairman.
Ms. Callahan joined Cingulate in 2017, bringing decades of executive leadership, finance and accounting experience. Beginning her career with Deloitte, she served in various roles in the firm’s audit practice. Ms. Callahan holds a CPA designation and received a BSBA in Accounting and Finance from Creighton University.
Ms. Callahan continues to be supported by a seasoned executive team that includes Dr. Matt Brams (Cingulate Co-Founder and Chief Medical Officer), Dr. Raul Silva (Cingulate Co-Founder and Chief Science Officer) and Nilay Patel (Chief Legal Officer) all of whom have extensive experience in the ADHD category.
About Cingulate Inc.
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information, visit Cingulate.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. These statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on March 27, 2025, and our other filings with the SEC. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.
Investor & Media Relations:
Thomas Dalton
Vice President, Corporate Communications, Cingulate
tdalton@cingulate.com
(913) 942-2301
FAQ
Why was Cingulate (NASDAQ: CING) CEO Shane Schaffer placed on administrative leave?
Who is Jennifer Callahan, the new interim CEO of Cingulate?
What is the status of Cingulate's ADHD drug development?
Who are the key executives currently leading Cingulate?
